Analysis for RMD

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.22B to roughly $1.46B, a durable win of ~19%. Net income advanced from about $311M to around $383M, up ~23% with modest quarterly fluctuations. Gross margin sits in the upper 50s to around 60%, and Operating margin has typically ranged in the low- to mid-30s, signaling improving operating leverage.

💰 Margins & Cash Flow

Gross margin around 58–60%; Operating margin ~32–35%; Net margin ~25–28%. Cash flow from operations is robust, with the latest quarter near $454.6M; investing activities have been negative and financing activities also negative in many periods. The quarter’s overall net cash flow was about -$191.3M, suggesting disciplined capex and a solid balance sheet despite non-operating outflows.

🛡️ Balance Sheet & Liquidity

The balance sheet remains strong: Equity attributable to parent ~$6.59B, Assets ~$8.97B, and Liabilities ~$2.38B (Q4 2026). Long-term debt around $0.40B; current assets about $4.33B vs. current liabilities around $1.40B, implying a healthy liquidity cushion and current ratio near 3.1. These metrics reflect solid solvency and capacity to support operational needs.

⚠️ Key Drivers & Risks

• Drivers: steady demand for core respiratory/medical devices and connected health solutions; ongoing operating leverage gains.
• Risks: regulatory/payer exposure and competitive dynamics; valuation sensitivity to moderate growth assumptions.